Why the study?
Does KD3-671 reduce mean blood pressure in renal hypertensive dogs?
Population
Renal hypertensive dogs with normal or high plasma renin activity (PRA)
Comparison
KD3-671 at 3 and 10 mg/kg orally, single dose or… vs Enalapril at 3 mg/kg orally
Design
Preclinical
Follow-up
29 days
Authors
Loading...
Supports progression to human trials; leaves open clinical efficacy and safety in hypertension.
Does KD3-671 reduce mean blood pressure in renal hypertensive dogs?
KD3-671 demonstrates dose-dependent antihypertensive efficacy in a canine model of renal hypertension, supporting its potential utility for hypertension treatment.
Takata et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: